Ketamine infusions for depressive symptoms in intensive care
About this title
Read the official source — NCT07639359Researchers are comparing Ketamine (0.5 mg/kg) and placebo to find out how the approaches affect depression symptoms in people with depression.
Understand this study
What is this study about?
Researchers are comparing Ketamine (0.5 mg/kg) and placebo to find out how the approaches affect depression symptoms in people with depression.
Who could participate?
Listed age limits: 18 years to 99 years.
What will I do during this study?
Participants are randomly assigned to intravenous ketamine or saline placebo (an inactive comparison treatment). The infusion is given once daily over 40 to 60 minutes for two consecutive days, with monitoring during treatment.
- Listed locations
- Jacksonville and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- Hospital Italiano de Buenos Aires
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Argentina
- Age range
- From 18 Years to 99 Years
- Official registry ID
- NCT07639359
- Official title
Show the full official title
Ketamine In Depression - Intensive Care Unit Trial (KID-ICU): A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Ketamine Infusion for Depressive Symptoms in Intensive Care Unit Patients
Recruitment & locations
Jacksonville, United States · Buenos Aires, Argentina
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Ketamine (0.5 mg/kg) and placebo to find out how the approaches affect depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Hospital Italiano de Buenos Aires, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Ketamine (0.5 mg/kg).
Who can participate?
Listed age limits: 18 years to 99 years.
Is this study still recruiting?
The registry lists this study as recruiting.
